The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Trading Of Onyx Pharmaceuticals Common Stock Halted

Wednesday, June 20, 2012

Trading Of Onyx Pharmaceuticals Common Stock Halted12:55 EDT Wednesday, June 20, 2012- Advisory Committee of the Food and Drug Administration to Discuss Kyprolis? New Drug Application for the Treatment of Multiple Myeloma - - Conference Call Scheduled for 7:00 p.m. ET Today -SOUTH SAN FRANCISCO, Calif., June 20, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that NASDAQ has halted trading of the company's common stock.   The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this afternoon to discuss the company's New Drug Application (NDA) for Kyprolis? (proposed brand name for carfilzomib) under the accelerated approval pathway.The NDA for Kyprolis for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies that included a proteasome inhibitor and an immunomodulatory agent is currently being reviewed by the U.S. FDA, and the anticipated date for completion of review under the PDUFA guidelines is July 27, 2012.Conference Call TodayThe Onyx management team will host a webcast and conference call to discuss the ODAC recommendation today at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time). To access a live audio webcast of the conference call, log onto the company's website at: access the live conference call, dial (847) 585-4405 and use the passcode 32594605. A replay of the call will be available on the Onyx website or by dialing (630) 652-3042 and using the passcode 3259 4605# approximately two hours after the conference call concludes through July 4, 2012. About Onyx Pharmaceuticals, Inc.Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at SOURCE Onyx Pharmaceuticals, Inc.For further information: Investors, Amy Figueroa, Senior Director, Investor Relations, +1-650-266-2398, or Media, Danielle Bertrand, Senior Manager, Corporate Communications, +1-650-266-2114